JNJ - What's Going On With Danish Healthcare Firm Genmab Stock? | Benzinga
Monday, in a significant legal update for Genmab A/S (NASDAQ:GMAB), an appeal arbitrator has dismissed the biotech company’s bid for additional milestone and royalty payments related to Darzalex (daratumumab).
In an SEC filing, Genmab announced that the appeal arbitrator in its second arbitration arising under its license agreement with Janssen Biotech Inc, Johnson & Johnson’s (NYSE:JNJ) unit, for daratumumab had denied Genmab’s appeal.
As a result, the dismissal of Genmab’s claims in the second arbitration is now concluded. Genmab had appealed the tribunal’s two-to-one decision dismissing Genmab’s claims because the claims should have been brought in the prior arbitration between ...